News
December 12, 2022
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
December 1, 2022
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
November 22, 2022
TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 11, 2022
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
November 9, 2022
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
TScan Therapeutics Announces Upcoming Virtual Investor Event
November 3, 2022
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
October 5, 2022
TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
September 22, 2022
TScan Therapeutics to Participate in Upcoming Investor Conferences
September 12, 2022